S Matthijs Boekholdt

List of Publications by Year
in descending order

Source: //exaly.com/author-pdf/2807150/publications.pdf

Version: 2025-02-01

219 papers	20,991 citations	10113 67 h-index	7342 143 g-index
233 all docs	233 docs citations	233 times ranked	27713 citing authors

#	Article	IF	Citations
1	High-Risk Embolic Sources on Cardiac Computed Tomography in Patients With Acute Ischemic Stroke: A Case-Control Study. Stroke, 2025, 56, 420-426.	6.2	0
2	Long-term cardiac follow-up of athletes infected with SARS-CoV-2 after resumption of elite-level sports. Heart, 2024, 110, 254-262.	2.8	1
3	Longâ€Term Clinical Implications of Highâ€Risk Cardiac Computed Tomography Findings in Patients With Acute Ischemic Stroke. Journal of the American Heart Association, 2024, 13, .	4.3	1
4	Constrictive Pericarditis Caused by Primary Pericardial Mesothelioma: A Case Series. Circulation: Cardiovascular Imaging, 2024, 17, .	3.2	0
5	Left Atrial Appendage Opacification on Cardiac Computed Tomography in Acute Ischemic Stroke: TheÂClinical Implications of Slowâ€Flow. Journal of the American Heart Association, 2024, 13, .	4.3	4
6	Genetic Variance in Heparan Sulfation Is Associated With Salt Sensitivity. Hypertension, 2024, 81, 2101-2112.	7.0	0
7	ELITE: rationale and design of a longitudinal elite athlete, extreme cardiovascular phenotyping, prospective cohort study. BMJ Open Sport and Exercise Medicine, 2023, 9, e001505.	2.4	2
8	Impact of C-reactive protein levels on lipoprotein(a)-associated aortic stenosis incidence and progression. European Heart Journal Open, 2023, 3, .	2.8	3
9	Early Risk Stratification for Natural Disease Course in Fabry Patients Using Plasma Globotriaosylsphingosine Levels. Clinical Journal of the American Society of Nephrology: CJASN, 2023, 18, 1272-1282.	4.2	7
10	ANGPTL3 (Angiopoietinâ€Like 3) Preferentially Resides on Highâ€Density Lipoprotein in the Human Circulation, Affecting Its Activity. Journal of the American Heart Association, 2023, 12, .	4.3	3
11	Lipoprotein(a) has no major impact on calcification activity in patients with mild to moderate aortic valve stenosis. Heart, 2022, 108, 61-66.	2.8	23
12	Baffle Complications in Adults After Atrial Switch for Transposition of the Great Arteries. Canadian Journal of Cardiology, 2022, 38, 68-76.	1.9	3
13	Response to: Correspondence on "Lipoprotein(a) has no major impact on calcification activity in patients with mild to moderate aortic valve stenosis" by Pantelidis et al. Heart, 2022, 108, 576-577.	2.8	0
14	Higher anticholinergic burden from medications is associated with significant increase in markers of inflammation in the EPICâ€Norfolk prospective populationâ€based cohort study. British Journal of Clinical Pharmacology, 2022, 88, 3297-3306.	2.8	10
15	Standardizing the Cardiac Radioablation Targeting Workflow: Enabling Semi-Automated Angulation and Segmentation of the Heart According to the American Heart Association Segmented Model. Advances in Radiation Oncology, 2022, 7, 100928.	1.4	16
16	Confirmatory factor analysis including MRI-derived adipose tissues quantification improves associations of metabolic dysregulation to diastolic dysfunction. Journal of Diabetes and Its Complications, 2022, 36, 108202.	2.6	1
17	Relationship of Sodium Intake With Granulocytes, Renal and Cardiovascular Outcomes in the Prospective EPICâ€Norfolk Cohort. Journal of the American Heart Association, 2022, 11, .	4.3	1
18	Association of Circulating Monocyte Chemoattractant Proteinâ€“1 Levels With Cardiovascular Mortality. JAMA Cardiology, 2021, 6, 587.	9.7	39

#	Article	IF	Citations
19	Quantification of Myocardial Creatine and Triglyceride Content in the Human Heart: Precision and Accuracy of in vivo Proton Magnetic Resonance Spectroscopy. Journal of Magnetic Resonance Imaging, 2021, 54, 411-420.	3.7	14
20	Fully quantitative mapping of abnormal aortic velocity and wall shear stress direction in patients with bicuspid aortic valves and repaired coarctation using 4D flow cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 2021, 23, 9.	4.7	18
21	Retrospective Cameraâ€Based Respiratory Gating in Clinical Wholeâ€Heart <scp>4D</scp> Flow <scp>MRI</scp>. Journal of Magnetic Resonance Imaging, 2021, 54, 440-451.	3.7	9
22	Multimodality Evaluation of a Septal Cystic Cavity and Ventricular Septal Defect in the Setting of Neurocysticercosis and Endocarditis. Circulation: Cardiovascular Imaging, 2021, 14, .	3.2	0
23	Lipoprotein(a) is robustly associated with aortic valve calcium. Heart, 2021, 107, 1422-1428.	2.8	40
24	Plasma trimethylamine N-oxide (TMAO) levels predict future risk of coronary artery disease in apparently healthy individuals in the EPIC-Norfolk prospective population study. American Heart Journal, 2021, 236, 80-86.	2.9	47
25	Association between serum secretory phospholipase A2 and risk of ischaemic stroke. European Journal of Neurology, 2021, 28, 3650-3655.	3.7	2
26	Sex-Specific Associations of Genetically Predicted Circulating Lp(a) (Lipoprotein(a)) and Hepatic LPA Gene Expression Levels With Cardiovascular Outcomes: Mendelian Randomization and Observational Analyses. Circulation Genomic and Precision Medicine, 2021, 14, .	3.2	16
27	Impact of cholesterol on proinflammatory monocyte production by the bone marrow. European Heart Journal, 2021, 42, 4309-4320.	2.2	43
28	Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect. Nature Genetics, 2021, 53, 128-134.	16.3	172
29	Aortic dissection masquerading as a code stroke: A single-centre cohort study. European Stroke Journal, 2020, 5, 56-62.	4.1	9
30	Improved cardiovascular risk prediction using targeted plasma proteomics in primary prevention. European Heart Journal, 2020, 41, 3998-4007.	2.2	76
31	Mind the Heart: Electrocardiography-gated cardiac computed tomography-angiography in acute ischaemic strokeâ€"rationale and study design. European Stroke Journal, 2020, 5, 441-448.	4.1	7
32	Quantification of Mitral Valve Regurgitation from 4D Flow MRI Using Semiautomated Flow Tracking. Radiology: Cardiothoracic Imaging, 2020, 2, e200004.	3.1	19
33	Subclinical effects of longâ€chain fatty acid Î²â€oxidation deficiency on the adult heart: A caseâ€control magnetic resonance study. Journal of Inherited Metabolic Disease, 2020, 43, 969-980.	3.4	11
34	CT angiography vs echocardiography for detection of cardiac thrombi in ischemic stroke: a systematic review and meta-analysis. Journal of Neurology, 2020, 267, 1793-1801.	3.4	32
35	Genetic and InÂVitro Inhibition of PCSK9 and Calcific Aortic Valve Stenosis. JACC Basic To Translational Science, 2020, 5, 649-661.	3.5	54
36	Lipoprotein-associated phospholipase A2 activity, genetics and calcific aortic valve stenosis in humans. Heart, 2020, 106, 1407-1412.	2.8	15

#	Article	IF	Citations
37	Association of Long-term Exposure to Elevated Lipoprotein(a) Levels With Parental Life Span, Chronic Diseaseâ€“Free Survival, and Mortality Risk. JAMA Network Open, 2020, 3, e200129.	7.2	33
38	Outcomes of cardiac surgery after mediastinal radiation therapy: A singleâ€center experience. Journal of Cardiac Surgery, 2020, 35, 612-619.	0.9	13
39	A pooled-analysis of age and sex based coronary artery calcium scores percentiles. Journal of Cardiovascular Computed Tomography, 2020, 14, 414-420.	1.2	14
40	Association of FADS1/2 Locus Variants and Polyunsaturated Fatty Acids With Aortic Stenosis. JAMA Cardiology, 2020, 5, 694.	9.7	36
41	Lifestyle modification in older versus younger patients with coronary artery disease. Heart, 2020, 106, 1066-1072.	2.8	16
42	apoB/apoAâ€I Ratio and Lp(a) Associations With Aortic Valve Stenosis Incidence: Insights From the EPICâ€Norfolk Prospective Population Study. Journal of the American Heart Association, 2019, 8, .	4.3	18
43	Validation of the Systematic COronary Risk Evaluation - Older Persons (SCORE-OP) in the EPIC-Norfolk prospective population study. International Journal of Cardiology, 2019, 293, 226-230.	2.2	10
44	Circulating Monocyte Chemoattractant Protein-1 and Risk of Stroke. Circulation Research, 2019, 125, 773-782.	12.8	81
45	Genetic Variation in LPA, Calcific Aortic Valve Stenosis in Patients Undergoing Cardiac Surgery, and Familial Risk of Aortic Valve Microcalcification. JAMA Cardiology, 2019, 4, 620.	9.7	39
46	Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With AorticÂStenosis. Journal of the American College of Cardiology, 2019, 73, 2150-2162.	2.6	221
47	A 3-SNP gene risk score and a metabolic risk score both predict hypertriglyceridemia and cardiovascular disease risk. Journal of Clinical Lipidology, 2019, 13, 492-501.	2.0	4
48	Abnormal blood flow and wall shear stress are present in corrected aortic coarctation despite successful surgical repair. Journal of Cardiovascular Surgery, 2019, 60, .	0.8	4
49	Bileaflet mechanical aortic valves do not alter ascending aortic wall shear stress. International Journal of Cardiovascular Imaging, 2019, 35, 703-710.	1.3	9
50	Aortic dissection and prophylactic surgery in congenital heart disease. International Journal of Cardiology, 2019, 274, 113-116.	2.2	14
51	Smoking cessation after nurse-coordinated referral to a comprehensive lifestyle programme in patients with coronary artery disease: a substudy of the RESPONSE-2 trial. European Journal of Cardiovascular Nursing, 2019, 18, 113-121.	1.2	10
52	Myocardial fibrosis as an early feature in phospholamban p.Arg14del mutation carriers: phenotypic insights from cardiovascular magnetic resonance imaging. European Heart Journal Cardiovascular Imaging, 2019, 20, 92-100.	1.4	47
53	Effect of Spironolactone on Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction: Post-Hoc Analysis of the Randomized, Placebo-Controlled TOPCAT Trial. American Journal of Cardiovascular Drugs, 2019, 20, 73-80.	2.6	32
54	The prognostic value of heart rate recovery in patients with coronary artery disease: A systematic review and meta-analysis. American Heart Journal, 2018, 199, 163-169.	2.9	22

#	Article	IF	Citations
55	Elevated lipoprotein(a) levels are associated with coronary artery calcium scores in asymptomatic individuals with a family history of premature atherosclerotic cardiovascular disease. Journal of Clinical Lipidology, 2018, 12, 597-603.e1.	2.0	34
56	Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial. Circulation, 2018, 138, 770-781.	19.4	141
57	Estimated individual lifetime benefit from PCSK9 inhibition in statin-treated patients with coronary artery disease. Heart, 2018, 104, 1699-1705.	2.8	13
58	Aortic valve stenosis and aortic diameters determine the extent of increased wall shear stress in bicuspid aortic valve disease. Journal of Magnetic Resonance Imaging, 2018, 48, 522-530.	3.7	47
59	Genetics, Clinical Features, and Long-TermÂOutcome of NoncompactionÂCardiomyopathy. Journal of the American College of Cardiology, 2018, 71, 711-722.	2.6	250
60	Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk. Journal of Clinical Lipidology, 2018, 12, 130-136.	2.0	46
61	Impact of physical activity on the risk of cardiovascular disease in middle-aged and older adults: EPIC Norfolk prospective population study. European Journal of Preventive Cardiology, 2018, 25, 200-208.	2.1	75
62	Effect of Losartan on Right Ventricular Dysfunction. Circulation, 2018, 137, 1463-1471.	19.4	42
63	Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study. Journal of Clinical Lipidology, 2018, 12, 1493-1501.e11.	2.0	7
64	Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting. European Heart Journal, 2018, 39, 2589-2596.	2.2	102
65	Life's simple 7 and calcific aortic valve stenosis incidence in apparently healthy men and women. International Journal of Cardiology, 2018, 269, 226-228.	2.2	19
66	Elixhauser Comorbidity Score Is the Best Risk Score in Predicting Survival After Mitraclip Implantation. Structural Heart, 2018, 2, 53-57.	1.8	8
67	Effect of Long-Term Low Lipoproteins on Neurocognitive Function. Journal of the American College of Cardiology, 2018, 72, 1176-1177.	2.6	2
68	Advanced cardiac MRI techniques for evaluation of leftâ€sided valvular heart disease. Journal of Magnetic Resonance Imaging, 2018, 48, 318-329.	3.7	37
69	Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1206-1212.	6.2	58
70	Lipoprotein(a) Improves Cardiovascular Risk PredictionÂBased on Established Risk Algorithms. Journal of the American College of Cardiology, 2017, 69, 1513-1515.	2.6	33
71	An Evidence-Based Guide to Cholesterol-Lowering Guidelines. Canadian Journal of Cardiology, 2017, 33, 343-349.	1.9	17
72	Nurse-coordinated care improves the achievement of LDL cholesterol targets through more intensive medication titration. Open Heart, 2017, 4, e000607.	2.5	5

#	Article	IF	Citations
73	Association of Highâ€Density Lipoproteinâ€Cholesterol Versus Apolipoprotein Aâ€I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancerâ€Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health Study. Journal of the American Heart Association, 2017, 6, .	4.3	14
74	Coronary Artery Disease Affects Symptomatology of Aortic Valve Stenosis. Journal of the American College of Cardiology, 2017, 70, 1103-1104.	2.6	1
75	Systolic anterior motion of the tricuspid valve in a patient with hypertrophic obstructive cardiomyopathy. Interactive Cardiovascular and Thoracic Surgery, 2017, 25, 496-497.	1.5	2
76	Community-Based Lifestyle Intervention in Patients With Coronary Artery Disease. Journal of the American College of Cardiology, 2017, 70, 318-327.	2.6	72
77	Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: The EPIC-Norfolk prospective population study. Atherosclerosis, 2017, 256, 47-52.	1.2	80
78	Carriers of the PCSK9 R46L Variant Are Characterized by an Antiatherogenic Lipoprotein Profile Assessed by Nuclear Magnetic Resonance Spectroscopyâ€"Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 43-48.	6.2	24
79	Very low LDL-cholesterol concentrations achieved: which target is next?. Lancet, The, 2017, 390, 1930-1931.	35.3	3
80	Human Cardiac 31P-MR Spectroscopy at 3 Tesla Cannot Detect Failing Myocardial Energy Homeostasis during Exercise. Frontiers in Physiology, 2017, 8, .	3.0	30
81	Four-dimensional flow MRI of stented versus stentless aortic valve bioprostheses. European Radiology, 2017, 28, 257-264.	3.8	14
82	Meta-analysis of genome-wide association studies of HDL cholesterol response to statins. Journal of Medical Genetics, 2016, 53, 835-845.	3.7	30
83	Dilation of the Aorta Ascendens Forms Part of the Clinical Spectrum of HCN4 Mutations. Journal of the American College of Cardiology, 2016, 67, 2313-2315.	2.6	27
84	Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 213-221.	4.5	12
85	Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population. Circulation, 2016, 134, 1419-1429.	19.4	192
86	Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study. Journal of Lipid Research, 2016, 57, 697-705.	3.7	29
87	Câ€Reactive Protein Identifies Lowâ€Risk Metabolically Healthy Obese Persons: The European Prospective Investigation of Cancerâ€"Norfolk Prospective Population Study. Journal of the American Heart Association, 2016, 5, .	4.3	21
88	Effective components of nurse-coordinated care to prevent recurrent coronary events: a systematic review and meta-analysis. Heart, 2016, 102, 50-56.	2.8	33
89	Detailed characterization of familial idiopathic ventricular fibrillation linked to the DPP6 locus. Heart Rhythm, 2016, 13, 905-912.	0.8	49
90	Coronary artery calcification score as tool for risk assessment among families with premature coronary artery disease. Atherosclerosis, 2016, 245, 155-160.	1.2	8

#	Article	IF	Citations
91	Heterogeneous impact of classic atherosclerotic risk factors on different arterial territories: the EPIC-Norfolk prospective population study. European Heart Journal, 2016, 37, 880-889.	2.2	38
92	Estimated 10-year cardiovascular mortality seriously underestimates overall cardiovascular risk. Heart, 2016, 102, 63-68.	2.8	46
93	Ideal cardiovascular health and risk of cardiovascular events in the EPIC-Norfolk prospective population study. European Journal of Preventive Cardiology, 2016, 23, 986-994.	2.1	65
94	Non-high-density lipoprotein cholesterol. Current Opinion in Lipidology, 2015, 26, 502-510.	4.1	71
95	The Systematic COronary Risk Evaluation (SCORE) in a large UK population: 10-year follow-up in the EPIC-Norfolk prospective population study. European Journal of Preventive Cardiology, 2015, 22, 119-126.	2.1	23
96	Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study. Lancet Diabetes and Endocrinology,the, 2015, 3, 507-513.	22.3	397
97	PLA2G10 Gene Variants, sPLA2 Activity, and Coronary Heart Disease Risk. Circulation: Cardiovascular Genetics, 2015, 8, 356-362.	4.2	17
98	Reply. Journal of the American College of Cardiology, 2015, 65, 109.	2.6	0
99	Habitual chocolate consumption and risk of cardiovascular disease among healthy men and women. Heart, 2015, 101, 1279-1287.	2.8	65
100	Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk?. Circulation, 2015, 132, 433-440.	19.4	28
101	Community-based comprehensive lifestyle programs in patients with coronary artery disease: Objectives, design and expected results of Randomized Evaluation of Secondary Prevention by Outpatient Nurse SpEcialists 2 trial (RESPONSE 2). American Heart Journal, 2015, 170, 216-222.	2.9	13
102	Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nature Communications, 2014, 5, .	14.1	202
103	Lipoprotein(a) Levels, Genotype, and Incident Aortic Valve Stenosis. Circulation: Cardiovascular Genetics, 2014, 7, 304-310.	4.2	232
104	Impact of abdominal obesity and systemic hypertension on risk of coronary heart disease in men and women. Journal of Hypertension, 2014, 32, 2224-2230.	1.2	8
105	The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. European Heart Journal, 2014, 35, 960-968.	2.2	261
106	Impact of High-Dose Atorvastatin Therapy and Clinical Risk Factors on Incident Aortic Valve Stenosis in Patients With Cardiovascular Disease (from TNT, IDEAL, and SPARCL). American Journal of Cardiology, 2014, 113, 1378-1382.	1.9	26
107	The Association Between Circulating Lipoprotein(a) and Type 2 Diabetes: Is It Causal?. Diabetes, 2014, 63, 332-342.	0.5	82
108	Added value of hybrid myocardial perfusion SPECT and CT coronary angiography in the diagnosis of coronary artery disease. European Heart Journal Cardiovascular Imaging, 2014, 15, 1281-1288.	1.4	31

#	Article	IF	Citations
109	Novel Genetic Approach to Investigate the Role of Plasma Secretory Phospholipase A2 (sPLA) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf	4.2	22
110	Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events. Journal of the American College of Cardiology, 2014, 64, 485-494.	2.6	509
111	Secretory Phospholipase A2-IIA and Cardiovascular Disease. Journal of the American College of Cardiology, 2013, 62, 1966-1976.	2.6	106
112	Levels and Changes of HDL Cholesterol and Apolipoprotein A-I in Relation to Risk of Cardiovascular Events Among Statin-Treated Patients. Circulation, 2013, 128, 1504-1512.	19.4	170
113	Hybrid myocardial perfusion SPECT/CT coronary angiography and invasive coronary angiography in patients with stable angina pectoris lead to similar treatment decisions. Heart, 2013, 99, 188-194.	2.8	35
114	Clinical implications of JUPITER in a contemporary European population: the EPIC-Norfolk prospective population study. European Heart Journal, 2013, 34, 1350-1357.	2.2	5
115	Response to letter by Balta et al.. International Journal of Cardiology, 2013, 169, 89.	2.2	2
116	Rates and determinants of progressive aortic valve dysfunction in aortic coarctation. International Journal of Cardiology, 2013, 167, 2841-2845.	2.2	5
117	Reply. Journal of the American College of Cardiology, 2013, 61, 1934.	2.6	5
118	Red cell distribution width is associated with physical inactivity and heart failure, independent of established risk factors, inflammation or iron metabolism; the EPICâ€"Norfolk study. International Journal of Cardiology, 2013, 168, 3550-3555.	2.2	57
119	Cardiovascular Event Reduction Versus New-Onset Diabetes During Atorvastatin Therapy. Journal of the American College of Cardiology, 2013, 61, 148-152.	2.6	153
120	Incremental diagnostic accuracy of hybrid SPECT/CT coronary angiography in a population with an intermediate to high pre-test likelihood of coronary artery disease. European Heart Journal Cardiovascular Imaging, 2013, 14, 642-649.	1.4	44
121	Title is missing!. Heart, 2013, 99, 1136.2-1137.	2.8	2
122	C-Reactive Protein, Fatal and Nonfatal Coronary Artery Disease, Stroke, and Peripheral Artery Disease in the Prospective EPIC-Norfolk Cohort Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 2888-2894.	6.2	42
123	A comparative analysis of three widely used lipid management guidelines in the EPIC-Norfolk cohort. European Journal of Preventive Cardiology, 2013, 20, 98-106.	2.1	3
124	High-sensitivity Troponin T Is Associated with Poor Outcome in Adults with Pulmonary Arterial Hypertension due to Congenital Heart Disease. Congenital Heart Disease, 2013, 8, 520-526.	0.5	34
125	Nonâ€<scp>HDL</scp> cholesterol vs. Apo B for risk of coronary heart disease in healthy individuals: the <scp>EPIC</scp>â€Norfolk prospective population study. European Journal of Clinical Investigation, 2013, 43, 1009-1015.	3.2	25
126	High-Dose Statin Therapy in Patients With Stable Coronary Artery Disease. Circulation, 2013, 127, 2485-2493.	19.4	36

#	Article	IF	Citations
127	Common genetic variants do not associate with CAD in familial hypercholesterolemia. European Journal of Human Genetics, 2013, 22, 809-813.	3.1	3
128	Clinical and Biological Relevance of Statin-Mediated Changes in HDL Metabolism. Current Atherosclerosis Reports, 2013, 16, .	4.9	6
129	The 719Arg Variant of KIF6 and Cardiovascular Outcomes in Statin-Treated, Stable Coronary Patients of the Treating to New Targets and Incremental Decrease in End Points Through Aggressive Lipid-Lowering Prospective Studies. Circulation: Cardiovascular Genetics, 2012, 5, 51-57.	4.2	20
130	Lipoprotein(a) and Risk of Coronary, Cerebrovascular, and Peripheral Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 3058-3065.	6.2	158
131	Relationship between atorvastatin dose and the harm caused by torcetrapib. Journal of Lipid Research, 2012, 53, 2436-2442.	3.7	8
132	Association of LDL Cholesterol, Nonâ€“HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins. JAMA - Journal of the American Medical Association, 2012, 307, 1302.	13.7	636
133	Determinants of Residual Risk in Secondary Prevention Patients Treated With High- Versus Low-Dose Statin Therapy. Circulation, 2012, 125, 1979-1987.	19.4	148
134	Lipid-Related Markers and Cardiovascular Disease Prediction. JAMA - Journal of the American Medical Association, 2012, 307, .	13.7	337
135	Lipid Parameters and Cardiovascular Events in Patients Taking Statinsâ€”Reply. JAMA - Journal of the American Medical Association, 2012, 308, 131.	13.7	0
136	De-risking the clinical development of cholesteryl ester transfer protein inhibitors: how much is good enough?. European Heart Journal, 2012, 33, 1548-1550.	2.2	6
137	The interleukin-6 pathway and atherosclerosis. Lancet, The, 2012, 379, 1176-1178.	35.3	38
138	Surgical versus percutaneous treatment of aortic coarctation: new standards in an era of transcatheter repair. Expert Review of Cardiovascular Therapy, 2012, 10, 1517-1531.	1.8	35
139	On-Treatment Nonâ€“High-Density Lipoprotein Cholesterol, Apolipoprotein B, Triglycerides, and Lipid Ratios in Relation to Residual Vascular Risk After Treatment With Potent Statin Therapy. Journal of the American College of Cardiology, 2012, 59, 1521-1528.	2.6	91
140	Validation of a model to investigate the effects of modifying cardiovascular disease (CVD) risk factors on the burden of CVD: the rotterdam ischemic heart disease and stroke computer simulation (RISC) model. BMC Medicine, 2012, 10, .	7.4	11
141	Usefulness of coronary calcium scoring to myocardial perfusion SPECT in the diagnosis of coronary artery disease in a predominantly high risk population. International Journal of Cardiovascular Imaging, 2012, 29, 677-684.	1.3	4
142	Inflammatory biomarkers, physical activity, waist circumference, and risk of future coronary heart disease in healthy men and women. European Heart Journal, 2011, 32, 336-344.	2.2	92
143	Physical activity, metabolic syndrome, and coronary risk: the EPICâ€“Norfolk prospective population study. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 209-217.	2.8	47
144	Hypertriglyceridemic waist: missing piece of the global cardiovascular risk assessment puzzle?. Clinical Lipidology, 2011, 6, 639-651.	1.0	6

#	Article	IF	Citations
145	Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nature Genetics, 2011, 43, 333-338.	16.3	1,542
146	Adiponectin and Risk of Coronary Heart Disease in Apparently Healthy Men and Women (from the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.9	33
147	Varespladib: targeting the inflammatory face of atherosclerosis. European Heart Journal, 2011, 32, 923-926.	2.2	7
148	Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study. Journal of Lipid Research, 2011, 52, 1829-1836.	3.7	114
149	Lipid parameters for measuring risk of cardiovascular disease. Nature Reviews Cardiology, 2011, 8, 197-206.	12.5	174
150	The Authors' reply. Heart, 2011, 97, 684-684.	2.8	0
151	The Role of Non-HDL Cholesterol in Risk Stratification for Coronary Artery Disease. Current Atherosclerosis Reports, 2011, 14, 130-134.	4.9	50
152	Comprehensive Lipid Profiling Beyond LDL. , 2011, , 107-118.		1
153	Toll-like receptor 4 gene polymorphisms show no association with the risk of clinical or angiographic restenosis after percutaneous coronary intervention. Pharmacogenetics and Genomics, 2010, 20, 544-552.	1.3	7
154	Should we change our lipid management strategies to focus on non-high-density lipoprotein cholesterol?. Current Opinion in Cardiology, 2010, 25, 622-626.	1.8	7
155	Initial thyroid status and cardiovascular risk factors: The EPICâ€Norfolk prospective population study. Clinical Endocrinology, 2010, 72, 404-410.	2.5	132
156	Lipid assessment, metabolic syndrome and coronary heart disease risk. European Journal of Clinical Investigation, 2010, 40, 1081-1093.	3.2	28
157	Biological, clinical and population relevance of 95 loci for blood lipids. Nature, 2010, 466, 707-713.	40.1	2,933
158	Genetic Variation at the Phospholipid Transfer Protein Locus Affects Its Activity and High-Density Lipoprotein Size and Is a Novel Marker of Cardiovascular Disease Susceptibility. Circulation, 2010, 122, 470-477.	19.4	81
159	Chemokine Ligand 2 Genetic Variants, Serum Monocyte Chemoattractant Protein-1 Levels, and the Risk of Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 1460-1466.	6.2	18
160	PLA2G7 Genotype, Lipoprotein-Associated Phospholipase A ₂ Activity, and Coronary Heart Disease Risk in 10 494 Cases and 15 624 Controls of European Ancestry. Circulation, 2010, 121, 2284-2293.	19.4	98
161	Separating the Mechanism-Based and Off-Target Actions of Cholesteryl Ester Transfer Protein Inhibitors With CETP Gene Polymorphisms. Circulation, 2010, 121, 52-62.	19.4	84
162	Comparison between Gradient Gel Electrophoresis and Nuclear Magnetic Resonance Spectroscopy in Estimating Coronary Heart Disease Risk Associated with LDL and HDL Particle Size. Clinical Chemistry, 2010, 56, 789-798.	1.1	33

#	Article	IF	Citations
163	The Relationship Between Plasma Angiopoietin-like Protein 4 Levels, Angiopoietin-like Protein 4 Genotype, and Coronary Heart Disease Risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 2277-2282.	6.2	65
164	Genetic Variants Influencing Circulating Lipid Levels and Risk of Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 2264-2276.	6.2	349
165	The hypertriglyceridemic-waist phenotype and the risk of coronary artery disease: results from the EPIC-Norfolk Prospective Population Study. Cmaj, 2010, 182, 1427-1432.	1.4	142
166	Oxidation-Specific Biomarkers, Lipoprotein(a), and Risk of Fatal and Nonfatal Coronary Events. Journal of the American College of Cardiology, 2010, 56, 946-955.	2.6	130
167	Metabolic dyslipidemia and risk of future coronary heart disease in apparently healthy men and women: The EPIC-Norfolk prospective population study. International Journal of Cardiology, 2010, 143, 399-404.	2.2	30
168	Physical activity, the Framingham risk score and risk of coronary heart disease in men and women of the EPIC-Norfolk study. Atherosclerosis, 2010, 209, 261-265.	1.2	28
169	Lack of association between common genetic variation in endothelial lipase (LIPG) and the risk for CAD and DVT. Atherosclerosis, 2010, 211, 558-564.	1.2	35
170	C-reactive protein and cardiovascular risk: more fuel to the fire. Lancet, The, 2010, 375, 95-96.	35.3	22
171	C-reactive protein measurement and cardiovascular disease â€“ Authors' reply. Lancet, The, 2010, 375, 1077-1078.	35.3	1
172	HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet, The, 2010, 376, 333-339.	35.3	208
173	Rimonabant: obituary for a wonder drug. Lancet, The, 2010, 376, 489-490.	35.3	17
174	C-reactive protein is a mediator of cardiovascular disease. European Heart Journal, 2010, 31, 2087-2091.	2.2	162
175	Improving risk stratification for cardiovascular disease. Expert Review of Cardiovascular Therapy, 2010, 8, 1091-1093.	1.8	3
176	Family history of premature coronary heart disease and risk prediction in the EPIC-Norfolk prospective population study. Heart, 2010, 96, 1985-1989.	2.8	98
177	Both Paraoxonase-1 Genotype and Activity Do Not Predict the Risk of Future Coronary Artery Disease; the EPIC-Norfolk Prospective Population Study. PLoS ONE, 2009, 4, e6809.	2.5	43
178	Retinol-Binding Protein 4 and Prediction of Incident Coronary Events in Healthy Men and Women. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 255-260.	4.4	50
179	Osteoprotegerin and Soluble Receptor Activator of Nuclear Factor-Î¹B Ligand and Risk for Coronary Events. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 975-980.	6.2	69
180	Prolactin Levels and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women. Circulation: Cardiovascular Genetics, 2009, 2, 389-395.	4.2	45

#	Article	IF	Citations
181	Is myeloperoxidase a useful marker to predict the risk of cardiovascular events?. Current Cardiovascular Risk Reports, 2009, 3, 137-143.	1.8	2
182	Beyond Low-Density Lipoprotein Cholesterol. Journal of the American College of Cardiology, 2009, 55, 35-41.	2.6	261
183	High-Density Lipoprotein Particle Size and Concentration and Coronary Risk. Annals of Internal Medicine, 2009, 150, 84.	10.5	199
184	HDL particle size and the risk of coronary heart disease in apparently healthy men and women: The EPIC-Norfolk prospective population study. Atherosclerosis, 2009, 206, 276-281.	1.2	97
185	High-Density Lipoprotein Cholesterol, High-Density Lipoprotein Particle Size, and Apolipoprotein A-I: Significance for Cardiovascular Risk. Journal of the American College of Cardiology, 2008, 51, 634-642.	2.6	310
186	ANGPTL4E40K and T266M. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 2319-2325.	6.2	86
187	Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment. Circulation, 2008, 117, 3002-3009.	19.4	390
188	Evaluation of the Framingham Risk Score in the European Prospective Investigation of Cancerâ€“Norfolk Cohort<subtitle>Does Adding Glycated Hemoglobin Improve the Prediction of Coronary Heart Disease Events?</subtitle>. Archives of Internal Medicine, 2008, 168, 1209.	8.9	65
189	Inhibition of Lipoprotein-Associated Phospholipase Activity by Darapladib. Circulation, 2008, 118, 1120-1122.	19.4	14
190	Major Depression, C-Reactive Protein, and Incident Ischemic Heart Disease in Healthy Men and Women. Psychosomatic Medicine, 2008, 70, 850-855.	2.3	29
191	Apolipoprotein A-II Is Inversely Associated With Risk of Future Coronary Artery Disease. Circulation, 2007, 116, 2029-2035.	19.4	98
192	Circulating Secretory Phospholipase A2 Activity and Risk of Incident Coronary Events in Healthy Men and Women. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 1177-1183.	6.2	88
193	Cholesterol levels in small LDL particles predict the risk of coronary heart disease in the EPIC-Norfolk prospective population study. European Heart Journal, 2007, 28, 2770-2777.	2.2	48
194	Arterial Thrombosis and the Role of Thrombophilia. Seminars in Thrombosis and Hemostasis, 2007, 33, 588-596.	3.1	100
195	Triglycerides and the Risk of Coronary Heart Disease. Circulation, 2007, 115, 450-458.	19.4	1,157
196	Plasma levels of plant sterols and the risk of coronary artery disease: the prospective EPIC-Norfolk Population Study. Journal of Lipid Research, 2007, 48, 139-144.	3.7	105
197	Body Fat Distribution and Risk of Coronary Heart Disease in Men and Women in the European Prospective Investigation Into Cancer and Nutrition in Norfolk Cohort. Circulation, 2007, 116, 2933-2943.	19.4	386
198	Role of the Apolipoprotein Bâ€“Apolipoprotein A-I Ratio in Cardiovascular Risk Assessment: A Caseâ€“Control Analysis in EPIC-Norfolk. Annals of Internal Medicine, 2007, 146, 640.	10.5	126

#	Article	IF	Citations
199	Value of Low-Density Lipoprotein Particle Number and Size as Predictors of Coronary Artery Disease in Apparently Healthy Men and Women. Journal of the American College of Cardiology, 2007, 49, 547-553.	2.6	217
200	Serum Myeloperoxidase Levels Are Associated With the Future Risk of Coronary Artery Disease in Apparently Healthy Individuals. Journal of the American College of Cardiology, 2007, 50, 159-165.	2.6	514
201	C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: The EPIC-Norfolk prospective population study 1993â€“2003. Atherosclerosis, 2006, 187, 415-422.	1.2	135
202	Apolipoprotein A-V, triglycerides and risk of coronary artery disease: the prospective Epic-Norfolk Population Study. Journal of Lipid Research, 2006, 47, 2064-2070.	3.7	81
203	Serum Levels of Mannose-Binding Lectin and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2345-2350.	6.2	59
204	Cholesteryl Ester Transfer Protein (CETP) Inhibition Beyond Raising High-Density Lipoprotein Cholesterol Levels. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 706-715.	6.2	66
205	Physical activity, C-reactive protein levels and the risk of future coronary artery disease in apparently healthy men and women: the EPICâ€“Norfolk prospective population study. European Journal of Cardiovascular Prevention and Rehabilitation, 2006, 13, 970-976.	2.8	19
206	Serum Lipoprotein Lipase Concentration and Risk for Future Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 637-642.	6.2	62
207	Inherited disorders of HDL metabolism and atherosclerosis. Current Opinion in Lipidology, 2005, 16, 139-145.	4.1	87
208	Serum Levels of Type II Secretory Phospholipase A2 and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 839-846.	6.2	94
209	Relationship between In Vitro Lipopolysaccharide-Induced Cytokine Response in Whole Blood, Angiographic In-Stent Restenosis, and Toll-Like Receptor 4 Gene Polymorphisms. Clinical Chemistry, 2005, 51, 516-521.	1.1	11
210	Plasma Levels of Cholesteryl Ester Transfer Protein and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women. Circulation, 2004, 110, 1418-1423.	19.4	188
211	IL-8 Plasma Concentrations and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 1503-1508.	6.2	161
212	Interaction between a genetic variant of the platelet fibrinogen receptor and fibrinogen levels in determining the risk of cardiovascular events. American Heart Journal, 2004, 147, 181-186.	2.9	18
213	Macrophage migration inhibitory factor and the risk of myocardial infarction or death due to coronary artery disease in adults without prior myocardial infarction or stroke: The EPIC-Norfolk Prospective Population study. American Journal of Medicine, 2004, 117, 390-397.	2.1	75
214	CETP gene variation: relation to lipid parameters and cardiovascular risk. Current Opinion in Lipidology, 2004, 15, 393-398.	4.1	58
215	Molecular variation at the apolipoproteinï¿½B gene locus in relation to lipids and cardiovascular disease: a systematic meta-analysis. Human Genetics, 2003, 113, 417-425.	3.1	49
216	Variants of Toll-Like Receptor 4 Modify the Efficacy of Statin Therapy and the Risk of Cardiovascular Events. Circulation, 2003, 107, 2416-2421.	19.4	200

#	Article	IF	Citations
217	Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease. Journal of Lipid Research, 2003, 44, 1080-1093.	3.7	137
218	Thrombospondin-2 Polymorphism Is Associated With a Reduced Risk of Premature Myocardial Infarction. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, .	6.2	61
219	Lipoprotein(a) and progression of aortic valve calcification: a case of collider bias? Reply. European Heart Journal, 0, , .	2.2	1